Literature DB >> 19468703

[Cerebral CT and MRI in mitchondrial disorders].

J Finsterer1.   

Abstract

The central nervous system (CNS) is the second most frequently affected organ in mitochondrial disorders (MD). In the majority of the cases, clinical CNS manifestations correlate with the CNS lesions on imaging and vice versa. The most important method to demonstrate CNS abnormalities in MD is the MRI. This imaging technique can demonstrate structural lesions, such as strokelike lesions, focal or diffuse atrophy, cysts or lacunas, focal or diffuse white matter lesions, grey matter lesions of the cortex or deep grey matter, and increased iron deposition. Functional abnormalities such as increased lactate in the white and grey matter or increased cholin in the white matter can be demonstrated by proton spectroscopy. Abnormlities of the intracerebral vessels can also be documented by MRI. Calcification and bleeding, however, are still more easily accessible by CT. Differentiation between disseminated, focal MD lesions of the white matter from nonactive MS plaques requires inclusion of the individual and family history and all instrumental investigations which are usually necessary to establish the diagnosis of a MD.

Entities:  

Mesh:

Year:  2009        PMID: 19468703     DOI: 10.1007/s00115-009-2678-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  79 in total

1.  Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome.

Authors:  T Iizuka; F Sakai; N Suzuki; T Hata; S Tsukahara; M Fukuda; Y Takiyama
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

2.  Vascular involvement in mitochondrial myopathy.

Authors:  R Sakuta; I Nonaka
Journal:  Ann Neurol       Date:  1989-06       Impact factor: 10.422

3.  Cognitive dysfunction and hypogonadotrophic hypogonadism in a Brazilian patient with mitochondrial neurogastrointestinal encephalomyopathy and a novel ECGF1 mutation.

Authors:  F J Carod-Artal; M D Herrero; M C Lara; E López-Gallardo; E Ruiz-Pesini; R Martí; J Montoya
Journal:  Eur J Neurol       Date:  2007-05       Impact factor: 6.089

4.  [A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone].

Authors:  Kengo Maeda; Mariko Tatsumi; Masayuki Tahara; Yoshiko Murata; Hiromichi Kawai; Hitoshi Yasuda
Journal:  Rinsho Shinkeigaku       Date:  2005-06

5.  Progressive cerebral vascular degeneration with mitochondrial encephalopathy.

Authors:  Nicola Longo; Iris Schrijver; Hannes Vogel; Lynn M Pique; Tina M Cowan; Marzia Pasquali; Gary K Steinberg; Gary L Hedlund; Sharon L Ernst; Renata C Gallagher; Gregory M Enns
Journal:  Am J Med Genet A       Date:  2008-02-01       Impact factor: 2.802

6.  Cerebral white matter involvement in children with mitochondrial encephalopathies.

Authors:  I Moroni; M Bugiani; A Bizzi; G Castelli; E Lamantea; G Uziel
Journal:  Neuropediatrics       Date:  2002-04       Impact factor: 1.947

Review 7.  Brain magnetic resonance in the diagnostic evaluation of mitochondrial encephalopathies.

Authors:  Maria Cristina Bianchi; Giuseppina Sgandurra; Michela Tosetti; Roberta Battini; Giovanni Cioni
Journal:  Biosci Rep       Date:  2007-06       Impact factor: 3.840

8.  Mitochondrial encephalomyopathy associated with diabetes mellitus, cataract, and corpus callosum atrophy.

Authors:  Minoru Oishi; Kenji Miki; Akihiko Morita; Kazumi Fujioka; Shigeki Aoki; Ichizo Nishino; Ikuya Nonaka; Yu-ichi Goto; Tomohiko Mizutani
Journal:  Intern Med       Date:  2008-03-03       Impact factor: 1.271

9.  [Psychotic syndrome developing into dementia as a clinical manifestation of mitochondrial DNA deletion].

Authors:  Luiz Felipe Rocha Vasconcellos; Ana Claudia Celestino Leite; José Luis Sá Cavalcanti; Denise Madeira Moreira; Denise Feijó; Carolina Fischinger Moura de Souza
Journal:  Arq Neuropsiquiatr       Date:  2007-03       Impact factor: 1.420

10.  MR of the brain in mitochondrial myopathy.

Authors:  S H Wray; J M Provenzale; D R Johns; K R Thulborn
Journal:  AJNR Am J Neuroradiol       Date:  1995-05       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.